| Company/Division name | WuXi PharmaTech |
| Type of work | Manufacturing |
| If manufacturing, is the company an OEM? | Yes |
| Reshoring category: | Transplant |
| Year reshoring announced: | 2015 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 40 |
| Country(ies) from which reshored: | China |
| City reshored to: | Philadelphia |
| State(s) reshored to: | PA |
| If relevant, work nearshored to: | - |
| Industry(ies): | Medical Equipment/Supplies |
| Product(s) reshored | Cell Therapy Products |
| What domestic positive factors made reshoring more attractive? | Customer responsiveness improvement |
